Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.

@article{Kitange2012InhibitionOH,
  title={Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.},
  author={Gaspar J. Kitange and Ann C. Mladek and Brett L. Carlson and Mark A Schroeder and Jenny L. Pokorny and Ling Cen and P. Anthony Decker and Wenting Wu and Gwen A. Lomberk and Shiv K Gupta and Raul A Urrutia and Jann N. Sarkaria},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2012},
  volume={18 15},
  pages={4070-9}
}
PURPOSE The therapeutic benefit of temozolomide in glioblastoma multiforme (GBM) is limited by resistance. The goal of this study was to elucidate mechanisms of temozolomide resistance in GBM. EXPERIMENTAL DESIGN We developed an in vivo GBM model of temozolomide resistance and used paired parental and temozolomide-resistant tumors to define the mechanisms underlying the development of resistance and the influence of histone deacetylation (HDAC) inhibition. RESULTS Analysis of paired… CONTINUE READING